Skip to main content
Figure 4 | Molecular Pain

Figure 4

From: Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice

Figure 4

IL-1β production in the cancer-inoculated region and the effect by Z-360 treatment. A. B16/BL6 cells were injected into the plantar region of the right hind paw of C57BL/6 mice. On day 14 after transplantation, right hind paw samples were collected, homogenized, and subjected to an ELISA for the measurement of IL-1β. The results are reported as the mean ± S.E. (n = 12). ##, p < 0.01, normal versus B16/BL6 melanoma (Wilcoxon test). B. Z-360 (100 mg/kg) was administered orally once a day from day 7 to 14 after transplantation. A final dose of Z-360 was orally administered, and after 60 min, the levels of IL-1β were measured. The results are reported as the mean ± S.E. (n = 23-24). ###, p < 0.001, normal versus vehicle (Wilcoxon test); *, p < 0.05, vehicle versus Z-360 (Wilcoxon test).

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us